<?xml version="1.0" encoding="UTF-8"?>
<results title="test_trace">
 <result pre="intestine, kidney, and blood vessels. At present, no specific antiviral" exact="treatment" post="and no efficient vaccines are available for COVID-19 in"/>
 <result pre="Moreover, their preliminary data showed that it inhibits COVID-19 virus" exact="infection" post="also in human liver cancer (Huh-7) cells. Some clinical"/>
 <result pre="developed a pan-CoV fusion inhibitor, EK1 peptide, to inhibit the" exact="infection" post="of five human coronaviruses including SARS-CoV. The same group"/>
 <result pre="protein of COVID-19 virus could effectively inhibit COVID-19 pseudo virus" exact="infection" post="and domain S2 mediated cell fusion [2]. It has"/>
 <result pre="the increased expression of ACE2 [3]. It was hypothesised that" exact="treatment" post="with ACE2-stimulating drugs may facilitate the infection with COVID-19"/>
 <result pre="was hypothesised that treatment with ACE2-stimulating drugs may facilitate the" exact="infection" post="with COVID-19 virus and increase the risk of developing"/>
 <result pre="and increase the risk of developing severe fatal COVID-19 viral" exact="infection" post="[4]. The ACE2 gene polymorphisms might play important role"/>
 <result pre="antiviral drug, and it also has shown to inhibit viral" exact="infection" post="of SARS-CoV. In a recent study, it was shown"/>
 <result pre="it was shown that chloroquine efficiently inhibits the COVID-19 viral" exact="infection" post="in Vero E6 cells at entry and post-entry stages"/>
</results>
